October 19, 2006Annual Review of Medicine
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Authors
Discussion
Loading...
Member takes
Implication
Narrative review outlines the therapeutic inhibition of VEGF-A across malignancies and neovascular eye diseases, indicating its critical role in managing pathological angiogenesis.
Key Points
- To review the underlying biology of vascular endothelial growth factor-A (VEGF-A) and evaluate clinical advancements in targeting this pathway for the management of cancer and neovascular age-related macular degeneration.
- Synthesized molecular and translational research establishing VEGF-A as an essential mediator of physiological and pathological angiogenesis.
- Evaluated therapeutic development and regulatory approvals of targeted VEGF-A inhibitors across oncology and ophthalmology indications.
- Demonstrated that targeted inhibition of VEGF-A effectively suppresses aberrant neovascularization in both malignant tumors and ocular diseases.
- Identified multiple VEGF inhibitors that secured regulatory approval for treating various solid tumors and the neovascular form of age-related macular degeneration.
Cite This Study
Ferrara et al. (2006) studied this question.